JP2024531799A5 - - Google Patents

Info

Publication number
JP2024531799A5
JP2024531799A5 JP2024517163A JP2024517163A JP2024531799A5 JP 2024531799 A5 JP2024531799 A5 JP 2024531799A5 JP 2024517163 A JP2024517163 A JP 2024517163A JP 2024517163 A JP2024517163 A JP 2024517163A JP 2024531799 A5 JP2024531799 A5 JP 2024531799A5
Authority
JP
Japan
Prior art keywords
months
decitabine
effective amount
sedazulidine
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024517163A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024531799A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/076757 external-priority patent/WO2023049731A2/en
Publication of JP2024531799A publication Critical patent/JP2024531799A/ja
Publication of JP2024531799A5 publication Critical patent/JP2024531799A5/ja
Pending legal-status Critical Current

Links

JP2024517163A 2021-09-21 2022-09-21 骨髄異形成症候群をデシタビン及びセダズリジンを用いて処置する方法 Pending JP2024531799A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163246547P 2021-09-21 2021-09-21
US63/246,547 2021-09-21
PCT/US2022/076757 WO2023049731A2 (en) 2021-09-21 2022-09-21 Methods of treating myelodysplastic syndromes with decitabine and cedazuridine

Publications (2)

Publication Number Publication Date
JP2024531799A JP2024531799A (ja) 2024-08-29
JP2024531799A5 true JP2024531799A5 (cg-RX-API-DMAC7.html) 2025-09-30

Family

ID=85721229

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024517163A Pending JP2024531799A (ja) 2021-09-21 2022-09-21 骨髄異形成症候群をデシタビン及びセダズリジンを用いて処置する方法

Country Status (10)

Country Link
US (1) US20250000888A1 (cg-RX-API-DMAC7.html)
EP (1) EP4404940A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024531799A (cg-RX-API-DMAC7.html)
KR (1) KR20240064656A (cg-RX-API-DMAC7.html)
CN (1) CN118201622A (cg-RX-API-DMAC7.html)
AU (1) AU2022348907B2 (cg-RX-API-DMAC7.html)
CA (1) CA3232623A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024003537A (cg-RX-API-DMAC7.html)
TW (1) TW202327625A (cg-RX-API-DMAC7.html)
WO (1) WO2023049731A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023548303A (ja) 2020-10-29 2023-11-16 大塚製薬株式会社 癌を処置する為の医薬組成物及びその使用方法
AU2024265282A1 (en) * 2023-05-02 2025-12-18 Taiho Pharmaceutical Co., Ltd. Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2708264C (en) * 2007-12-10 2018-07-03 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
US10683552B2 (en) * 2014-11-25 2020-06-16 Presidents And Fellows Of Harvard College Clonal haematopoiesis
US11224610B2 (en) * 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
WO2021113688A1 (en) * 2019-12-05 2021-06-10 Sumitomo Dainippon Pharma Oncology, Inc. Combination therapies for treatment of myelodysplastic syndrome
EP4090335A1 (en) * 2020-01-17 2022-11-23 Novartis AG Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
LT4069254T (lt) * 2020-02-25 2024-10-10 Otsuka Pharmaceutical Co., Ltd. Kietos geriamosios vaisto formos, apimančios decitabiną ir cedazuridiną

Similar Documents

Publication Publication Date Title
JP2022180461A5 (cg-RX-API-DMAC7.html)
JP2023541432A5 (cg-RX-API-DMAC7.html)
JP2023041862A5 (cg-RX-API-DMAC7.html)
JP2024015120A5 (cg-RX-API-DMAC7.html)
JP2021527092A5 (cg-RX-API-DMAC7.html)
JP2012521435A5 (cg-RX-API-DMAC7.html)
JP2022537551A5 (cg-RX-API-DMAC7.html)
JP2014515373A5 (cg-RX-API-DMAC7.html)
JP2024516795A5 (cg-RX-API-DMAC7.html)
JP2022521233A5 (cg-RX-API-DMAC7.html)
JP2023549455A5 (cg-RX-API-DMAC7.html)
JP2021509395A5 (cg-RX-API-DMAC7.html)
JP2020522560A5 (cg-RX-API-DMAC7.html)
JP2025148449A5 (cg-RX-API-DMAC7.html)
JP2016505050A5 (cg-RX-API-DMAC7.html)
JP2022553888A5 (cg-RX-API-DMAC7.html)
JP2024540439A5 (cg-RX-API-DMAC7.html)
TWI341728B (en) Combinations comprising epothilones and anti-metabolites
JP2022177119A5 (cg-RX-API-DMAC7.html)
JP2024528731A5 (cg-RX-API-DMAC7.html)
JP2021517128A5 (cg-RX-API-DMAC7.html)
JP2025504984A5 (cg-RX-API-DMAC7.html)
JP2024520690A5 (cg-RX-API-DMAC7.html)
JP2022512158A5 (cg-RX-API-DMAC7.html)
CN115350194A (zh) 一种药物组合及其应用